Rituximab as first-line treatment of patients with follicular lymphoma (FL) and a low-burden tumor: Clinical and molecular evaluation.

被引：0
|
作者：
Solal-Celigny, P
Salles, G
Brousse, N
Eftekhari, P
Soubeyran, P
Lacotte, L
Deconinck, E
Haioun, C
Foussard, C
Sebban, C
Stamatoulas, A
Milpied, N
Boue, F
Taillan, B
Lederlin, P
Najman, A
Mathieu-Boue, A
Benzohra, A
Colombat, P
机构：
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2802
引用
收藏
页码：631A / 631A
页数：1
相关论文
共 50 条
  • [21] PHARMACOECONOMIC ANALYSIS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN SPANISH PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA
    Rubio-Terres, C.
    Gomez-Codina, J.
    Rios, Herranz E.
    Castro, A. J.
    Varela, C.
    Ray, J. A.
    VALUE IN HEALTH, 2008, 11 (06) : A481 - A481
  • [22] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Eliazar Sabater
    Armando López-Guillermo
    Antonio Rueda
    Antonio Salar
    Itziar Oyagüez
    Juan Manuel Collar
    Applied Health Economics and Health Policy, 2016, 14 : 465 - 477
  • [23] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Sabater, Eliazar
    Lopez-Guillermo, Armando
    Rueda, Antonio
    Salar, Antonio
    Oyaguez, Itziar
    Manuel Collar, Juan
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (04) : 465 - 477
  • [24] End of Rituximab Maintenance for Low-Tumor Burden Follicular Lymphoma
    Friedberg, Jonathan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (28) : 3093 - +
  • [25] Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma
    Lopez-Guillermo, Armando
    Caballero, Dolores
    Canales, Miguel
    Provencio, Mariano
    Rueda, Antonio
    Salar, Antonio
    LEUKEMIA & LYMPHOMA, 2011, 52 : 1 - 14
  • [26] Patterns Of First-Line Management Strategies In Older Adults With Follicular Lymphoma (FL)
    Rai, Ashish
    Nastoupil, Loretta J.
    Williams, Jessica N.
    Lipscomb, Joseph
    Ward, Kevin
    Howard, David H.
    Flowers, Christopher R.
    BLOOD, 2013, 122 (21)
  • [27] CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
    Marcus, R
    Imrie, K
    Belch, A
    Cunningham, D
    Flores, E
    Catalano, J
    Solal-Celigny, P
    Offner, F
    Walewski, J
    Raposo, J
    Jack, A
    Smith, P
    BLOOD, 2005, 105 (04) : 1417 - 1423
  • [28] Subcutaneous (SC) Mosunetuzumab (mosun) As First-Line Therapy for Patients (pts) with High Tumor-Burden Follicular Lymphoma (FL): First Results of a Multicenter Phase 2 Study
    Falchi, Lorenzo
    Okwali, Michelle
    Ghione, Paola
    Owens, Colette
    Hamlin, Paul A.
    Lue, Jennifer Kimberly
    Epstein-Peterson, Zachary D.
    Palomba, Maria Lia
    Kumar, Anita
    Torka, Pallawi
    Leslie, Lori A.
    Lopes, Alexandra Ferreira
    Martinova, Anastasia
    Wood, Lauren
    Grieve, Clare
    Amador, Walter Ramos
    Vardhana, Santosha A.
    Zelenetz, Andrew D.
    Salles, Gilles
    BLOOD, 2023, 142
  • [29] Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma
    Vicente, Fatima de la Cruz
    Cruz, Estrella Carrillo
    Rodriguez, Maria Sole
    Niebla, Ana Marin
    Herranz, Eduardo Rios
    Galiana, Maria Luz Martino
    Gonzalez, Jose Falantes
    Cuadrado, Isabel Montero
    Campos, Jose Gonzalez
    Tocino, Ildefonso Espigado
    Perez-Simon, Jose A.
    BLOOD, 2013, 122 (21)
  • [30] Evaluation of Tumor Burden for Predicting Survival in Patients with Follicular Lymphoma Receiving First-Line R-CHOP Treatment: Comparison of Different Definition of GELF Criteria
    Kato, Harumi
    Tange, Naoyuki
    Iriyama, Chisako
    Kojima, Yuki
    Taji, Hirofumi
    Kinoshita, Tomohiro
    Yatabe, Yasushi
    Nakamura, Shigeo
    Yamamoto, Kazuhito
    BLOOD, 2017, 130
12345